Michele Dal-Bo

List of Publications by Year
in descending order

113 papers	3,128 citations	159525 30 h-index	175177 52 g-index
113 all docs	113 docs citations	113 times ranked	3821 citing authors

#	Article	IF	Citations
1	Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical–Biomolecular Markers Significantly Associated With Toxicity. Clinical Pharmacology and Therapeutics, 2022, 111, 686-696.	2.3	8
2	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. International Journal of Infectious Diseases, 2021, 104, 441-451.	1.5	14
3	A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State. Cells, 2021, 10, 576.	1.8	7
4	Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. Pharmaceutics, 2021, 13, 1106.	2.0	7
5	Characterization of Thermoresponsive Poly-N-Vinylcaprolactam Polymers for Biological Applications. Polymers, 2021, 13, 2639.	2.0	20
6	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers, 2021, 13, 4387.	1.7	15
7	A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. International Journal of Molecular Sciences, 2021, 22, 1075.	1.8	6
8	<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. Haematologica, 2021, 106, 3125-3135.	1.7	12
9	Thermoresponsive Chitosan-Grafted-Poly(N-vinylcaprolactam) Microgels via Ionotropic Gelation for Oncological Applications. Pharmaceutics, 2021, 13, 1654.	2.0	9
10	Chitosan-Based Biocompatible Copolymers for Thermoresponsive Drug Delivery Systems: On the Development of a Standardization System. Pharmaceutics, 2021, 13, 1876.	2.0	10
11	HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	1.7	39
12	A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 233-242.	0.6	5
13	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. Journal of Oncology, 2020, 2020, 1-15.	0.6	33
14	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers, 2020, 12, 1668.	1.7	54
15	A Novel Comprehensive Clinical Stratification Model to Refine Prognosis of Glioblastoma Patients Undergoing Surgical Resection. Cancers, 2020, 12, 386.	1.7	13
16	Biallelic <i><scp>BIRC</scp>3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. British Journal of Haematology, 2019, 185, 156-159.	1.2	9
17	New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers, 2019, 11, 1086.	1.7	41
18	A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. Cancers, 2019, 11, 1562.	1.7	31

#	Article	IF	Citations
19	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	1.3	28
20	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. Haematologica, 2019, 104, e410-e414.	1.7	5
21	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	3.3	21
22	Expression of the transcribed ultraconserved region 70 and the related long non‐coding <scp>RNA AC</scp>092652.2‐202 has prognostic value in Chronic Lymphocytic Leukaemia. British Journal of Haematology, 2019, 184, 1045-1050.	1.2	10
23	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. Haematologica, 2018, 103, 849-856.	1.7	21
24	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	4.2	65
25	<i><scp>NOTCH</scp>1</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. British Journal of Haematology, 2018, 182, 597-602.	1.2	22
26	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. Leukemia, 2018, 32, 654-662.	3.3	31
27	Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S214.	0.2	0
28	SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. Blood, 2018, 132, 1838-1838.	0.6	0
29	KRAS, NRAS and BRAF Mutations Are Highly Enriched in TRI12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. Blood, 2018, 132, 3113-3113.	0.6	0
30	Mutations in the 3′ untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. Haematologica, 2017, 102, e305-e309.	1.7	18
31	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia, 2017, 31, 2407-2415.	3.3	52
32	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	1.7	11
33	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE. Hematological Oncology, 2017, 35, 109-110.	0.8	1
34	Low‐dose radiotherapy in diffuse large B‐cell lymphoma. Hematological Oncology, 2017, 35, 472-479.	0.8	9
35	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia, 2016, 30, 2011-2018.	3.3	41
36	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	1.7	53

#	Article	IF	Citations
37	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Nano Research, 2016, 9, 537-548.	5.8	17
38	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia, 2016, 30, 182-189.	3.3	74
39	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. Leukemia, 2016, 30, 513-517.	3.3	3
40	Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs of Today, 2016, 52, 249.	0.7	18
41	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. Current Cancer Drug Targets, 2016, 16, 659-668.	0.8	11
42	Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 3204-3204.	0.6	0
43	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 306-306.	0.6	0
44	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 4354-4354.	0.6	0
45	HIF-1± Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	0.6	0
46	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. Blood, 2016, 128, 3195-3195.	0.6	0
47	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. Blood, 2016, 128, 4358-4358.	0.6	1
48	The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential. Oncotarget, 2015, 6, 19381-19392.	0.8	51
49	The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia, 2015, 29, 503-507.	3.3	84
50	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. Oncotarget, 2015, 6, 19102-19117.	0.8	18
51	Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication. Blood, 2015, 126, 1708-1708.	0.6	0
52	The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1720-1720.	0.6	0
53	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 1718-1718.	0.6	0
54	Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. Blood, 2015, 126, 701-701.	0.6	0

#	Article	IF	Citations
55	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. Leukemia, 2014, 28, 705-708.	3.3	10
56	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2014, 7, 79.	6.9	22
57	Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. Blood, 2014, 124, 3831-3833.	0.6	27
58	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. Seminars in Hematology, 2014, 51, 168-176.	1.8	32
59	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology, 2014, 93, 1765-1774.	0.8	34
60	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. Blood, 2014, 124, 296-296.	0.6	5
61	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 1978-1978.	0.6	0
62	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 2013, 121, 1403-1412.	0.6	420
63	Clinical significance of c.7544–7545 del*CT* *NOTCH1* mutation in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 415-418.	1.2	14
64	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	6.9	14
65	*ARHGDIA*, a mutant *TP*53–associated Rho *GDP* dissociation inhibitor, is over–expressed in gene expression profiles of *TP*53 disrupted chronic lymphocytic leukaemia cells. British Journal of Haematology, 2013, 161, 596-599.	1.2	3
66	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood, 2013, 121, 4902-4905.	0.6	113
67	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood, 2013, 122, 3317-3321.	0.6	48
68	Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 1370-1370.	0.6	1
69	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia, 2012, 26, 1301-1312.	3.3	78
70	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy. Current Pharmaceutical Design, 2012, 18, 3323-3334.	0.9	17
71	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica, 2012, 97, 279-287.	1.7	32
72	The miR-17–92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia, 2012, 26, 1584-1593.	3.3	77

#	ARTICLE	IF	CITATIONS
73	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. Blood, 2012, 120, 929-929.	0.6	1
74	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2870-2870.	0.6	0
75	Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4581-4581.	0.6	0
76	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. Blood, 2012, 120, 930-930.	0.6	0
77	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. Blood, 2012, 120, 1772-1772.	0.6	0
78	Bâ€cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. British Journal of Haematology, 2011, 153, 3-14.	1.2	30
79	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2011, 50, 633-643.	1.5	67
80	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leukemia and Lymphoma, 2010, 51, 822-838.	0.6	9
81	<i>IGHD3â€3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 149, 299-302.	1.2	1
82	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53^{wildâ€type} CLL with a poor cytotoxic response to Nutlinâ€3. British Journal of Haematology, 2010, 150, 237-239.	1.2	27
83	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. Leukemia, 2010, 24, 480-483.	3.3	7
84	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	3.2	44
85	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. Journal of Translational Medicine, 2010, 8, 23.	1.8	19
86	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	0.6	0
87	Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table). Current Cancer Drug Targets, 2009, 9, 510-518.	0.8	11
88	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. Cancer Research, 2009, 69, 4001-4009.	0.4	153
89	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. British Journal of Haematology, 2009, 144, 492-506.	1.2	106
90	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. Journal of Translational Medicine, 2009, 7, 76.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. Leukemia, 2008, 22, 224-226.	3.3	8
92	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood, 2008, 111, 865-873.	0.6	226
93	Comprehensive characterization of IGHV3-21–expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood, 2007, 109, 2989-2998.	0.6	62
94	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia, 2007, 21, 965-972.	3.3	57
95	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. Blood, 2007, 110, 3089-3089.	0.6	0
96	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. Journal of Translational Medicine, 2006, 4, 11.	1.8	9
97	B-Cell Chronic Lymphocytic Leukemia. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 154-160.	0.6	2
98	CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia, 2006, 20, 523-525.	3.3	51
99	Reply to Pittner et al.. Leukemia, 2006, 20, 528-529.	3.3	10
100	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia Research, 2006, 30, 1197-1199.	0.4	17
101	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. Cytometry Part B - Clinical Cytometry, 2006, 70B, 284-292.	0.7	38
102	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. Journal of Cellular Physiology, 2006, 207, 354-363.	2.0	49
103	Gene Expression Profiling (GEP) of CD38-Expressing/Unmutated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells by Using a Statistical Approach Suitable for Analysis of Unbalanced Datasets.. Blood, 2006, 108, 2089-2089.	0.6	0
104	Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?. Leukemia, 2005, 19, 1490-1492.	3.3	23
105	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. Journal of Immunological Methods, 2005, 305, 20-32.	0.6	17
106	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. Journal of Cellular Physiology, 2005, 204, 113-123.	2.0	30
107	Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2005, 6, 251-252.	1.4	3
108	Mutational Status of IgVH Genes in B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Prognosis: Percent Mutations or Evaluation of Antigen-Driven Selection?. Blood, 2005, 106, 2106-2106.	0.6	0

#	Article	IF	Citations
109	Analysis of IgVH gene mutations in BÂcell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. British Journal of Haematology, 2004, 126, 29-42.	1.2	54
110	Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2004, 5, 123-126.	2.1	9
111	Error-Prone DNA Polymerases iota and beta Are Over-Expressed in B-CLL Cells: Correlation with Specific IgVH Point-Mutations and Implication for the Pathogenesis of Intraclonal IgVH Diversification.. Blood, 2004, 104, 950-950.	0.6	1
112	Immunophenotypic clustering of B-Cell chronic lymphocytic leukemia (B-CLL) reveals a good prognosis disease subset characterized by the coordinated over-expression of CD62L, CD54, CD49c, CD25 And CD55. Journal of Clinical Oncology, 2004, 22, 6567-6567.	0.8	1
113	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0